Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. (ATOS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
atos · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Atossa Therapeutics, Inc. (ATOS) measures how much investors pay for each dollar of the company's trailing earnings. ATOS's current PE ratio of N/A is calculated by dividing its stock price of $4.50 by its TTM earnings per share of -$4.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2009 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Atossa Therapeutics, Inc.You ATOS | $39M | N/A | — | -$4.37 |
 Cognition Therapeutics, Inc. CGTX | $89M | N/A | — | -$0.32 |
 Clene Inc. CLNN | $58M | N/A | — | -$2.65 |
 Coya Therapeutics, Inc. COYA | $84M | N/A | — | -$1.27 |
 Greenwich LifeSciences, Inc. GLSI | $330M | N/A | — | -$1.43 |
 Immix Biopharma, Inc. IMMX | $435M | N/A | — | -$0.89 |
 Oncolytics Biotech Inc. ONCY | $86M | N/A | — | -$0.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.04 | — | |
2024-12-31 FY2024 | — | $-3.04 | — | |
2023-12-31 FY2023 | — | $-3.58 | — | |
2022-12-31 FY2022 | — | $-3.19 | — | |
2021-12-31 FY2021 | — | $-2.64 | — | |
2020-12-31 FY2020 | — | $-23.65 | — | |
2019-12-31 FY2019 | — | $-30.43 | — | |
2018-12-31 FY2018 | — | $-41.15 | — | |
2017-12-31 FY2017 | — | $-124.99 | — | |
2016-12-31 FY2016 | — | $-388.96 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Atossa Therapeutics, Inc. (ATOS) measures how much investors pay for each dollar of the company's trailing earnings. ATOS's current PE ratio of N/A is calculated by dividing its stock price of $4.50 by its TTM earnings per share of -$4.37.
Frequently asked questions
ATOS pe ratio · 6 questionsATOS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.50 and TTM EPS of -$4.37. Data sourced from Financial Modeling Prep via ATOS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Atossa Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09